Fig. 6From: Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA reviewTreatment difference of change from baseline in CDR‐SB, MMSE, ADAS-Cog 13, and ADCS‐ADL-MCI at week 78 grouped by study, dose, and ApoE carrier status and including or excluding post‐ARIA observations (× – Study 302, ο – Study 301, C – carrier, NC – non‐carrier; solid line is the line of unity)Back to article page